AZ’s IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the

New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma

With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments

→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs

AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the